Wealth Enhancement Advisory Services LLC acquired a new stake in Boston Scientific Co. (NYSE:BSX – Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,328 shares of the medical equipment provider’s stock, valued at approximately $367,000.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Forum Financial Management LP boosted its holdings in shares of Boston Scientific by 1.8% in the first quarter. Forum Financial Management LP now owns 11,903 shares of the medical equipment provider’s stock valued at $596,000 after acquiring an additional 205 shares in the last quarter. Dubuque Bank & Trust Co. lifted its stake in shares of Boston Scientific by 4.3% in the 1st quarter. Dubuque Bank & Trust Co. now owns 5,112 shares of the medical equipment provider’s stock valued at $256,000 after purchasing an additional 209 shares during the last quarter. Montag A & Associates Inc. lifted its position in Boston Scientific by 8.5% during the 4th quarter. Montag A & Associates Inc. now owns 2,712 shares of the medical equipment provider’s stock worth $125,000 after acquiring an additional 212 shares during the last quarter. Childress Capital Advisors LLC lifted its position in Boston Scientific by 3.5% during the 4th quarter. Childress Capital Advisors LLC now owns 6,201 shares of the medical equipment provider’s stock worth $287,000 after acquiring an additional 212 shares during the last quarter. Finally, Relyea Zuckerberg Hanson LLC increased its holdings in shares of Boston Scientific by 1.5% during the 1st quarter. Relyea Zuckerberg Hanson LLC now owns 15,306 shares of the medical equipment provider’s stock worth $766,000 after purchasing an additional 223 shares during the period. 92.20% of the stock is currently owned by institutional investors.
Insider Activity at Boston Scientific
In other Boston Scientific news, EVP Arthur C. Butcher sold 6,697 shares of the stock in a transaction on Wednesday, June 21st. The shares were sold at an average price of $53.80, for a total value of $360,298.60. Following the completion of the sale, the executive vice president now owns 17,453 shares in the company, valued at $938,971.40. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Arthur C. Butcher sold 6,697 shares of the firm’s stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $53.80, for a total transaction of $360,298.60. Following the completion of the sale, the executive vice president now owns 17,453 shares in the company, valued at approximately $938,971.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Eric Francis Yves Thepaut sold 83,401 shares of the firm’s stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $52.49, for a total transaction of $4,377,718.49. Following the sale, the executive vice president now owns 12,269 shares of the company’s stock, valued at approximately $643,999.81. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 176,779 shares of company stock valued at $9,360,777. Corporate insiders own 0.53% of the company’s stock.
Boston Scientific Price Performance
Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, April 26th. The medical equipment provider reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.04. The business had revenue of $3.39 billion for the quarter, compared to analyst estimates of $3.16 billion. Boston Scientific had a net margin of 6.91% and a return on equity of 14.57%. Boston Scientific’s revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.39 earnings per share. Sell-side analysts forecast that Boston Scientific Co. will post 1.95 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research analysts have recently issued reports on BSX shares. Raymond James boosted their price objective on shares of Boston Scientific from $56.00 to $60.00 and gave the stock a “strong-buy” rating in a report on Monday, April 17th. Piper Sandler upped their target price on shares of Boston Scientific from $58.00 to $62.00 in a research note on Thursday, July 6th. BTIG Research upped their target price on shares of Boston Scientific from $53.00 to $54.00 and gave the company a “buy” rating in a research note on Monday, April 17th. Citigroup upped their target price on shares of Boston Scientific from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, April 3rd. Finally, Royal Bank of Canada upped their target price on shares of Boston Scientific from $56.00 to $58.00 in a research note on Wednesday. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and a consensus target price of $56.56.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Featured Articles
- Five stocks we like better than Boston Scientific
- Contrarian Play: Beyond Meat Is At An Inflection Point
- Alibaba Just Flashed Green, Very Green
- This Small Cap Stock Surged Over 100%
- The CPI Data Isn’t As Good As You Think It Is
- How to Invest in Gold and Silver
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
